Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 173-176

  Van Ingen, Jakko ^a,b   Totten, Sarah E ^a   Heifets, Leonid B ^a   Boeree, Martin J ^b   Daley, Charles L ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; Ethambutol; Mycobacterium simiae; Nontuberculous mycobacteria; Pharmacokinetics; Rifampicin

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM LENTIFLAVUM; MYCOBACTERIUM PARASCROFULACEUM; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM STOMATEPIAE; MYCOBACTERIUM TRIPLEX; PRIORITY JOURNAL; RADIOMETRY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; OPPORTUNISTIC INFECTIONS; TREATMENT FAILURE; UNITED STATES; YOUNG ADULT;

EID: 84855518847     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.09.019     Document Type: Article

References (17)

1. Griffith DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
2. van Ingen J, Boeree MJ, Dekhuijzen PNR, van Soolingen D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008;31:106-9.
3. Kassarova V, Weissfeiler J, Krasznay E. Occurrence of atypical mycobacteria in Macacus rhesus. Acta Microbiol Acad Sci Hung 1965;12:275-82.
4. Springer B, Stockman L, Teschner K, Roberts GD, Böttger EC. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. J Clin Microbiol 1996;34:296-303. (Pubitemid 26035100)
5. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003;16:319-54. (Pubitemid 36519815)
6. O'Brien RJ, Geiter LJ, Snider Jr DE. The epidemiology of nontuberculous mycobacterial diseases in the United States. Am Rev Respir Dis 1987;135:1007-14. (Pubitemid 18021482)
7. Kirschner P, Springer B, Vogel U, Meier A, Wrede A, Kiekenbeck M, et al. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol 1993;31:2882-9. (Pubitemid 23318373)
8. Hall L, Doerr A, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine mycobacteriology laboratory. J Clin Microbiol 2003;41:1447-53. (Pubitemid 36428087)
9. Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993;31:2332-8. (Pubitemid 23254196)
10. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009;48:1685-94.
11. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-55. (Pubitemid 38669936)
12. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic - pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010;54:1728-33.
13. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-4.
14. Marshall HM, Carter R, Torbey MJ, Minion S, Tolson C, Sidjabat HE, et al. Mycobacterium lentiflavum in drinking water supplies, Australia. Emerg Infect Dis 2011;17:395-402.
15. Turenne CY, Cook VJ, Burdz TV, Pauls RJ, Thibert L, Wolfe JN, et al. Mycobacterium parascrofulaceum sp. nov., novel slowly growing, scotochromogenic clinical isolates related to Mycobacterium simiae. Int J Syst Evol Microbiol 2004;54:1543-51. (Pubitemid 39359967)
16. Piersimoni C, Zitti P, Mazzarelli G, Mariottini A, Nista D, Zallocco D. Mycobacterium triplex pulmonary disease in immunocompetent host. Emerg Infect Dis 2004;10:1859-62. (Pubitemid 39319383)
17. Pourahmad F, Cervellione F, Thompson KD, Taggart JB, Adams A, Richards RH. Mycobacterium stomatepiae sp. nov., a slowly growing, non-chromogenic species isolated from fish. Int J Syst Evol Microbiol 2008;58:2821-7.